| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04209543 | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) | PHASE3 | COMPLETED | 1,570 | — | — | Dec 30, 2019 | Feb 8, 2024 | Jan 29, 2025 | 224 | United States, Argentina +12 |
| NCT04090957 | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II) | PHASE3 | COMPLETED | 1,015 | — | — | Sep 27, 2019 | Aug 18, 2022 | Dec 26, 2025 | 117 | United States, Canada |
The weekly frequency of moderate to severe VMS at Baseline and Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 4. Mean change = mean weekly frequency at Week 4 - mean weekly frequency at Baseline
The weekly frequency of moderate to severe VMS at Baseline and Week 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 12. Mean change = mean weekly frequency at Week 12 - mean weekly frequency at Baseline
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3. The mean severity score of VMS at Baseline and Week 4 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of moderate and severe VMS observed at Week 4. Baseline and Week 4 severity score = \[(2 x number of moderate VMS) + (3 x number of severe VMS)\]/ (total number of moderate + severe VMS). Mean change = mean severity score at Week 4 - mean severity score at Baseline
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3. The mean severity score of VMS at Baseline and Week 12 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of moderate and severe VMS observed at Week 12. Baseline and Week 12 severity score = \[(2 x number of moderate VMS) + (3 x number of severe VMS)\]/ (total number of moderate + severe VMS). Mean change = mean severity score at Week 12 - mean severity score at Baseline
Endometrial biopsies will be centrally evaluated by three independent expert pathologists from different institutions, blinded to treatment group and to each other's readings. The concurrence of two of the three pathologists will be accepted as the final diagnosis. If there is no agreement among the three pathologists, the most severe pathologic diagnosis, i.e., atypical hyperplasia \>complex hyperplasia \>simple hyperplasia \>benign endometrium, will be used as the final diagnosis.
Weekly frequency of moderate to severe VMS at Baseline = total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (Week 0). Weekly frequency of moderate to severe VMS at Week X = total number (sum) of all recorded moderate to severe VMS experienced during the week X.
Mean severity score of VMS at Baseline: arithmetic mean of daily severity score values of moderate and severe VMS during the last 7 days prior randomization (Week 0). Mean severity score of VMS at Week 4 or 12: arithmetic mean of daily severity score values of moderate and severe VMS during Week 4 or 12. Daily severity score of VMS at Baseline = \[(2 x number of moderate VMS) + (3 x number of severe VMS)\]/(total number of moderate + severe VMS)\], if at least one moderate to severe VMS was recorded during the day. If documented absence of moderate to severe VMS during the day, daily severity was set to zero. Daily severity score of VMS Post-Baseline = \[(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)\]/(total number of mild + moderate + severe VMS)\], if at least one mild to severe VMS was recorded during the day. If documented absence of VMS during the day, daily severity was set to zero. Severity score: mild=1, moderate=2, severe=3.
| Arm | Type | Description |
|---|---|---|
| Estetrol 15 mg - Efficacy Part | EXPERIMENTAL | Estetrol (E4) 15 mg was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks. |
| Estetrol 20 mg - Efficacy Part | EXPERIMENTAL | Estetrol (E4) 20 mg was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks. |
| Placebo - Efficacy Part | PLACEBO_COMPARATOR | Placebo was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks. |
| Estetrol 20 mg + P4 100 mg - Safety Part | EXPERIMENTAL | Estetrol (E4) 20 mg and Progesterone (P4) 100 mg was administered once daily for up to 53 weeks. |
| Estetrol 15 mg - Efficacy Study Part | EXPERIMENTAL | Estetrol (E4) 15 mg, administered orally once daily for up to 53 weeks. |
| Estetrol 20 mg - Efficacy Study Part | EXPERIMENTAL | Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks. |
| Placebo - Efficacy Study Part | PLACEBO_COMPARATOR | Placebo, administered orally once daily for up to 53 weeks. |
| Estetrol 20 mg - Safety Study Part | EXPERIMENTAL | Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks. |
| Name | Type | Description |
|---|---|---|
| Estetrol | DRUG | Estetrol oral tablet: administered orally once daily |
| Placebo | DRUG | Placebo oral tablet: administered orally once daily |
| Progesterone | DRUG | Progesterone oral tablet: administered orally once daily |
| Estetrol oral tablet | DRUG | Estetrol oral tablet, administered orally once daily. |
| Placebo oral tablet | DRUG | Placebo oral tablet, administered orally once daily. |
Inclusion Criteria: * Signed and dated written informed consent form and any required privacy authorization prior to the initiation of any trial procedure, after the nature of the trial has been explained according to local regulatory requirements; * Females, ≥ 40 up to ≤ 65 years of age at randomi...